[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]

Abstract

The clinical case described concerns a 56-years old woman with triple-negative breast cancer metastic to bone progressed with previous chemotherapy and immunotherapy. Our patient, treated in second line with sacituzumab govitecan, obtained prolonged disease control without severe toxicity e with good quality of life.